Home | Bias 32% Exposed--raw data versus journal articles | FDA in Crisis | Wrong Drugs Used in Dementia | Bisphonphonates & Calcitonin for Osteoporosis don't work | Antidepressants don't work | Drug ads make people sick | adverse drug reactions--frequency | Atrovent (ipratropium) another killer | Anemia drugs Epoetin and Procrit kill | drugs and cognitive impairment | Lunesta, a sleeping pill, with negative results | DIABETES DRUG KILLS | Zyprexa weight gain, Lilly sued | Darvocet pulled in GB, but not here | Leading Researcher Creates Favorable Data
Lunesta, a sleeping pill, with negative results

Drug News--disappointing

From Worstpill.org, a consumer advocacy group linked to common cause (Ralph Nader).  This is one of hundreds of warnings which they have put out over the last decade.  Drug business is into profit first.  The results below are typical of this conflict of interest. 

New research shows that cognitive behavior therapy is superior to the sleeping pill zopiclone (IMOVANE) for treating short- and long-term insomnia in adults.  During the course of the research, patients receiving cognitive behavioral therapy improved their sleep efficiency (percentage of time asleep while in bed) from 81.4 percent before treatment to 90.1 percent after six months.  By comparison, patients in the zopiclone group experienced a decrease in percentage of time asleep from 82.3 percent to 81.9 percent over the course of the study.


Norwegian researchers published the results of the study in the June 28, 06, Journal of the American Medical Association (JAMA).  The study was funded in part by the University of Bergen in Norway and the Norwegian Foundation for Health and Rehabilitation.  


Zopiclone is not available for sale in the United States, but it has been available in 85 other countries since 1987.  However, the sleeping pill eszopiclone (LUNESTA), which is very popular in the United States, is a very similar drug.  Eszopiclone and zopiclone include the same drug, but zopiclone also includes a mirror image version of the eszopiclone—such combination is called an enantiomorphs.  Enantiomorphs mixtures are, when adjusted for potency, essentially the same as the other form which only has the most active form of the two mirror image.  Espzopiclone was listed as a Do Not Use drug in the July 2005 Worst Pills, Best Pills News.  More than three million prescriptions were dispensed for this drug in 2005, with sales that exceed $250 million in 2005.

Enter supporting content here

Those who have a financial interest in the outcome manipulate the results